Compare Amgen, Inc. (AMGN) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SoFi Technologies Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while SoFi Technologies Inc trades at $19.14 (market cap $24.09B). The key difference: Amgen, Inc. is far larger — about 8.1× SoFi Technologies Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | SOFI | |
|---|---|---|
Market Cap | $196.12B | $24.09B |
Sector | Health | Financials |
52-Week High | $388.16 | $32.21 |
52-Week Low | $271.18 | $15.15 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SoFi Technologies (SOFI) trades at $18.78, up 0.86% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $3.61B in 2025, though net income dipped to $481M. The company expanded its ETF lineup with SFYI and acquired AI investing agent Composer, driving positive media coverage. Support sits at $18, resistance at $19.
Outlook: SoFi's bank charter and digital expansion offer growth, but high P/E (41.73) and volatile cash flows pose risks. Analyst consensus target is $22.43 (17% upside), yet mixed ratings reflect execution concerns. Key risks include interest rate sensitivity and competitive fintech pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
